Developing Tomorrow’s Treatments
Anaveon is well positioned to be a leader in the field of engineered
Anaveon’s mission is to transform cytokines into life-saving treatments. The Company was founded in 2017 by experts in cutting-edge immunology, who wanted to design and develop patient treatments that benefit society.
This remains our vision today. Anaveon is a biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. The team has the skills to make this vision a reality: we are committed to transforming immunological insights into life-saving therapies.
Others share our vision, and investors have backed Anaveon with funding of more than 146 million CHF (€140 million).
Our dedicated team of drug developers is already 27 strong and growing. Anaveon’s expert scientists have decades of experience in drug development. Their expertise and drive to deliver tangible results are what sets our company apart.
Since 2017, Anaveon has grown in size and strength.
The first drug we are testing in clinical trials is
ANV419 – a selective
Company Information Pack
Discover Anaveon®
Read about Anaveon’s work towards our mission to transform cytokines into life-saving treatments. In this downloadable info package, you can find out more about the company, our team of dedicated experts, the drugs we are assessing in clinical trials, and the programs we have in the pipeline.
Want to know more?
To ask us a question, or find out about collaboration opportunities, email us at contact@anaveon.com.
Anaveon®’s pipeline based on engineered cytokines
Anaveon is exploiting the power of cytokines to orchestrate immune responses through safe and effective treatments for a variety of serious diseases. Our pipeline reflects this: we are developing
a unique no-alpha
Discovery
Lead Optimization
Preclinical Development
Phase I/II
Phase1
Lead Optimization
Discovery
Therapeutic Areas
The programs in Anaveon’s pipeline have potential across a range of therapeutic areas.
Solid
tumors
Cytokine immunotherapies could be used to treat solid tumors, including melanoma, renal cell cancer and bladder cancer.
Hematological
malignancies
Cancers of the blood, bone marrow and lymph nodes are potential targets, including leukemia, lymphoma and myeloma.
Combination
therapy
The programs in Anaveon’s pipeline could be used in combination with checkpoint inhibitors, innate immunity agonists, targeted agents or depleting antibodies.
Combination with
cell therapies
In combination with cutting-edge cell therapies, Anaveon’s programs could offer new benefits for cancer patients.
Quick Facts
- ANV419 is a fusion protein of
IL-2 with ananti-IL-2 antibody - In vitro and in vivo, ANV419 selectively signals through the IL-2Rβ/γ and promotes the expansion of both NK and CD8+ T cells but not Tregs
- ANV419 is currently in first human studies to determine the optimal dose for safety and efficacy
- Development in multiple cancer indications are initiating in 2022
Competitive Advantage
ANV419 has already displayed exceptional safety in early clinical studies and non-human primates. It is selective by design: ANV419 only promotes the function of CD8+ T cells and NK cells as immune effector cells while sparing regulatory T cells. Therefore, it is a potential treatment for a range of cancer types.
Latest Publications
ANV419 is a novel CD122 selective IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T cell and NK cell stimulatory function in vitro and in vivo
SITC Annual Meeting. 2020 Nov 9-14
Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human Interleukin-2
Sci Transl Med. 2016 Nov 30;8(367):367ra166.
Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms
Immunity. 2015 May 19;42(5):815-25
Start your journey with Anaveon® today
News
05
June
2023
Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual Meeting
Trial in Progress: OMNIA-2, Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma
03
June
2023
Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting
OMNIA-1, a Phase I/II study of ANV419, an IL- 2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma
18
April
2023
23
March
2023
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for Cancer Research (AACR) 23rd Annual Meeting being held from Friday, April 14, 2023, to Wednesday, April 19, 2023, in Orlando, Florida.
16
March
2023
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
Anaveon, a clinical stage, immuno-oncology company, today announced the first patient dosed with ANV419 in the OMNIA-2 (ANV419-102) study – a Phase I/II study assessing the safety, tolerability and preliminary efficacy of ANV419 for the treatment of patients with relapsed / refractory multiple myeloma as monotherapy and in combination with daratumumab and hyaluronidase-fihj1, or with lenalidomide plus dexamethasone. ANV419 is a powerful, IL-2Rb selective IL-2 agonist, which has been specifically designed to enable the delivery of high dose IL-2.